ACR Convergence 2021 Archives - Page 34 of 132

Abstract Number: 1922

Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom
Abstract Number: 1796

Early Identification of Psoriatic Arthritis with Axial Involvement Among Patients with Psoriasis: A Prospective Multicenter Study
Abstract Number: 0931

Early Improvement in Disease Activity Indices Predicts Achievement of Long-term Clinical Remissions, ASDAS Inactive Disease and Low BASDAI with Normal CRP, During TNF-α-inhibitor Therapy in Patients with Ankylosing Spondylitis
Abstract Number: 1301

Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Abstract Number: 1851

Early Intervention with Immunomodulators Leads to Better Outcomes in Patients with Systemic Sclerosis
Abstract Number: 0801

Early Remission at 6 Months as a Predictor of Longterm Remission in New Onset Rheumatoid Arthritis
Abstract Number: 0669

Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review
Abstract Number: 0153

Echogenic and Hypervascular Synovium Detected on Ultrasound Are Predictive of a Favorable Response After Intra-articular Corticosteroid Injection in Patients with Knee Osteoarthritis
Abstract Number: 0143

Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Abstract Number: 0240

Economic Burden of Fatigue Among Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Abstract Number: 0881

Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach
Abstract Number: 1734

Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
Abstract Number: 0058

Effect of Anti-inflammatory Drugs on Intestinal Epithelial Damage and Bacterial Translocation in the Adjuvant-induced Arthritis Model
Abstract Number: L14

Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis
Abstract Number: 1754

Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis
Abstract Number: 0268

Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
Abstract Number: 0858

Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Antiphospholipid Antibodies
Abstract Number: 0750

Effect of Deucravacitinib on the Psoriatic Arthritis Impact of Disease Questionnaires 12 and 9: Analysis of a Phase 2 Study of Active Psoriatic Arthritis
Abstract Number: 1629

Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Abstract Number: 1569

Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation
Abstract Number: 1330

Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Abstract Number: 0414

Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study
Abstract Number: 1846

Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial
Abstract Number: 0188

Effect of Nintedanib on Categorical Changes in FVC in Patients with Progressive Fibrosing ILDs: Further Analyses of the INBUILD Trial
Abstract Number: 0403

Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Abstract Number: 0661

Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
Abstract Number: 1527

Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
Abstract Number: 0921

Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial
Abstract Number: 1300

Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
Abstract Number: 0930

Effect of Tofacitinib on Spinal Vertebral Body and Posterolateral Element Inflammation and Structural Lesions Using the Canada-Denmark MRI Scoring System in Patients with Ankylosing Spondylitis: Results from a Phase 2 Study
Abstract Number: 1080

Effect of Triage by a Rheumatologist in a Primary Care Setting
Abstract Number: 1529

Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Abstract Number: 1679

Effectiveness and Safety of Tocilizumab SC Every 10 Days in Patients with Rheumatoid Arthritis Who Previously Used Tocilizumab EV During the COVID 19 Pandemic at the Hospital Docente Padre Billini, Dominican Republic
Abstract Number: 1674

Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study
Abstract Number: 0599

Effectiveness of a Provider Led Intervention on Medication Adherence in an Urban Lupus Clinic
Abstract Number: 0243

Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results from the PRCSG/PRINTO JIA Real-World Registry
Abstract Number: 1442

Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Abstract Number: 1077

Effectiveness of Non-Pharmacological Interventions to Promote Work Participation of People with Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Regression Analysis
Abstract Number: 1120

Effectiveness of Stretching and Bracing for the Treatment of Osteoarthritis-associated Joint Contractures Prior to Joint Replacement: A Systematic Review
Abstract Number: 1926

Effectiveness of the Making It Work™ Program at Improving Absenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
Abstract Number: 0588

Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR’s RISE Registry
Abstract Number: 1405

Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Abstract Number: 1412

Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
Abstract Number: 0833

Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Abstract Number: 0560

Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
Abstract Number: 1732

Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract Number: 1677

Effects of Biological-DMARDs on the Serum Low-density Lipoprotein (LDL) / High-density Lipoprotein (HDL) – Cholesterol Ratio in Patients with Rheumatoid Arthritis
Abstract Number: 0935

Effects of Ixekizumab Treatment on Structural Changes in the Sacroiliac Joints Based on MRI Assessments at 16 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 0224

Effects of Kinesiophobia and Physical Function on Physical Activity in Adults with Knee Osteoarthritis
Abstract Number: 0222

Effects of Multi-Joint Osteoarthritis Phenotypes on Self-Reported Physical Function over 3.5 Years: The Johnston County Osteoarthritis Project
Abstract Number: 1356

Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis
Abstract Number: 1702

Efficacy and Safety of Baricitinib in B/tsDMARDs Naive and B/tsDMARDs-IR Patients with Rheumatoid Arthritis
Abstract Number: 0488

Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
Abstract Number: 1336

Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Abstract Number: 0912

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients with Early versus Late Disease Through Week 52 of GO-ALIVE Study
Abstract Number: 1844

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
Abstract Number: 1685

Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – Placebo and Active Controlled Study
Abstract Number: 1686

Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy
Abstract Number: 0453

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Integrated Results from 2 Phase 3, Randomized, Double-blind Clinical Trials for CsDMARD-IR and Bio-IR Patients
Abstract Number: 0183

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients
Abstract Number: L13

Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study
Abstract Number: 0924

Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Abstract Number: 1421

Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study
Abstract Number: 0497

Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
Abstract Number: 1149

Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis
Abstract Number: 1740

Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
Abstract Number: 1742

Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials
Abstract Number: 1820

Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: L20

Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
Abstract Number: 1811

Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies
Abstract Number: 1667

Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression
Abstract Number: 1183

Efficacy of Rapid Transition of a Musculoskeletal/Rheumatology/Dermatology Course to Online Learning During COVID-19 Pandemic
Abstract Number: 0108

Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
Abstract Number: 0917

Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomised Controlled Trial in Axial SpA
Abstract Number: 0725

Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia
Abstract Number: 1809

Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Abstract Number: 1823

Efficacy of Upadacitinib in Patients with Active Psoriatic Arthritis and a Low or High Swollen Joint Count: A Subgroup Analysis of 2 Phase 3 Studies
Abstract Number: 1945

Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
Abstract Number: 1752

Efficacy of Voclosporin in Recent Onset Lupus Nephritis
Abstract Number: 0039

Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?
Abstract Number: 1571

Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
Abstract Number: 1645

Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis
Abstract Number: 1518

Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
Abstract Number: 0075

Endothelial Cell-activating Antibodies in COVID-19
Abstract Number: 0045

Endothelial Cells from Patients with DMARD Naïve, Active Inflammatory Arthritis Demonstrate Pro-inflammatory Sensitisation That Is Reversed by Therapy Initiation
Abstract Number: 1433

Endothelium-protective, Histone-neutralizing Properties of the Polyanionic Agent Defibrotide
Abstract Number: 0737

Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression
Abstract Number: 1014

Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis
Abstract Number: 0977

Enhancement of Patient and Clinician Partnerships in Juvenile Idiopathic Arthritis Management Using a Point-of-Care Dashboard: Development and Pilot Testing
Abstract Number: 1020

Enhancing Endothelial Cell Barrier Function via Sphingosine -1 Phosphate Receptor 1 (S1PR1) – a Novel Treatment for Experimental Arthritis
Abstract Number: 0561

Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports
Abstract Number: 0350

EPI-SIGN: Epigenetic SLE Indicators of Glomerular Nephritis
Abstract Number: 1050

Epidemiology and Clinical Features of Ophthalmological Manifestations in Behçet’s Disease: Study of 50 Patients of a Series of 120 Patients in a Region in Northern Spain
Abstract Number: 1543

Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study
Abstract Number: 1326

Epidemiology of Comorbidities in an Incident Psoriasis Cohort: A Population-Based Study
Abstract Number: 1027

Epidemiology of Latent Tuberculosis Infection in Patients with Rheumatic Immune-mediated Diseases: Single University Study of 1117 Patients
Abstract Number: 1633

Epidemiology of Musculoskeletal Manifestations in Paediatric Inflammatory Bowel Disease: A Systematic Review
Abstract Number: 1861

Epidermal Growth Factor Receptor Pathway and Fibrosis in Systemic Sclerosis Skin
Abstract Number: 1512

Epigenetic and Transcriptional Programs of CD4+ T Cell Anergy
Abstract Number: 1695

Erythrocyte Methotrexate Polyglutamates Are Substantially Higher After Subcutaneous Methotrexate Treatment in Rheumatoid Arthritis Patients in the First Months of Treatment
Abstract Number: 0396

Esophageal Involvement and Gastroesophageal Reflux Disease in Patients with SSc-ILD: Data from a Sub-Study of the SENSCIS Trial
Abstract Number: 1170

Establishment and Validation of a Didactic Musculoskeletal Ultrasound Course for Dermatologists Using an Innovative Handheld Ultrasound System
Abstract Number: 1048

Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
Abstract Number: 1764

Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients
Abstract Number: 0622

Ethnic Disparities in Giant-Cell Arteritis: A Clinical Comparison Among Caucasian and Hispanic Patients in the Inland Empire of Southern California
Abstract Number: 0610

Evaluating Patient No Show Rates to Rheumatology Appointments Across a Regional Healthcare System
Abstract Number: 1066

Evaluation of a Non-Face to Face Multidisciplinary Health Care Model in a Population with Rheumatoid ArthritisVulnerable to Covid-19 in a Health Emergency Situation
Abstract Number: 1701

Evaluation of Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis Patients, Treated with Biological Agents: 6-month Follow-up
Abstract Number: 1160

Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Abstract Number: 0088

Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data
Abstract Number: 1420

Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 1211

Evaluation of the Cervical Involvement Frequency and Associated Risk Factors in Patients with Rheumatoid Arthritis
Abstract Number: 1029

Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry
Abstract Number: 0770

Evaluation of the Lupus Low Disease Activity State (LLDAS) vs. the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K Score in a Pediatric Systemic Lupus Erythematosus Cohort
Abstract Number: 0859

Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus
Abstract Number: 0908

Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
Abstract Number: 1530

Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients
Abstract Number: 0937

Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Abstract Number: 1216

Evidence of a Tendency for Localized Recurrence of Arthritis in Rheumatoid Arthritis Patients
Abstract Number: 1887

Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment
Abstract Number: 0028

Evolution of Anti-modified Protein Antibody Responses Can Be Driven by Consecutive Exposure to Different Post-translational Modifications
Abstract Number: 0782

Examining the Association of Socioenvironmental Factors with Depression and Anxiety Symptoms Among Youth with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1214

Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
Abstract Number: 1124

Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Abstract Number: 1001

Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis
Abstract Number: 1009

Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 1436

Expanded PD-1hi CXCR5- HLA-DR+ T Cells Is Associated with Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 1549

Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?
Abstract Number: 1176

Experience from TheMednet: Online Rheumatology Physician Social Network
Abstract Number: 1151

Experiences and Finding Meaning Among Latin Americans Living with Lupus: Learning from Social Media Narratives by Patients and Their Social Network
Abstract Number: 1067

Experiences of Self-Care During the COVID-19 Pandemic Among Individuals with Rheumatoid Arthritis: A Qualitative Study
Abstract Number: 1070

Experiences of Wearable Technology by Persons with Knee Osteoarthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Lens
Abstract Number: 1071

Experiences Using Wearable Technology by Persons with Rheumatoid Arthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Analysis
Abstract Number: 0316

Exploring Alternative Responder Definitions for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) for Use in Sjögren’s Clinical Trials
Abstract Number: 1162

Exploring Cannabis Use and Perspectives Among Psoriatic Disease Patients
Abstract Number: 1714

Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases
Abstract Number: 1047

Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain
Abstract Number: 1500

Expression of Neuropilin-1 Is Significantly Increased in Dendritic Cells and CD4 + T Cells and It Correlates Disease Activity in the Patients with Systemic Lupus Erythematosus
Abstract Number: 0684

Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy
Abstract Number: 0514

Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 0303

Extraglandular Manifestations as Initial Presentation in a Cohort of Patients with Primary Sjögren’s Syndrome
Abstract Number: 1094

Extremely Elevated Erythrocyte Sedimentation Rate Revisited in Rheumatic Diseases: Flare-Up or Infection? Single Centre Retrospective Analysis
Abstract Number: 0194

Eye Opening: Use of IL-6 Inhibition in Non-Paraneoplastic Autoimmune Retinopathy